DGAP-Ad-hoc: PAION AG / Key word(s): Agreement 
???????PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND 
XERAVA(TM) (ERAVACYCLINE) IN EUROPE 
12-Jan-2021 / 13:40 CET/CEST 
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a 
service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND XERAVA 
(TM) (ERAVACYCLINE) IN EUROPE 
 
- PAION in-licenses exclusive rights to commercialize GIAPREZA(TM) and XERAVA(TM) throughout Europe 
- La Jolla Pharmaceutical Company to receive USD 22.5 million upfront payment, up to USD 109.5 million in commercial 
milestone payments, and double-digit tiered royalty payments 
- PAION to accelerate building its commercial organization in Europe to prepare for launches of GIAPREZA(TM), XERAVA 
(TM) and Byfavo^(R) (remimazolam) in Europe during 2021 
 
Aachen (Germany), 12 January 2021 - The Specialty Pharma Company, PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange 
Prime Standard: PA8) and its wholly owned subsidiary PAION Deutschland GmbH (collectively PAION), today announce that 
they entered into an exclusive license agreement with La Jolla Pharmaceutical Company and certain of its wholly owned 
subsidiaries (collectively La Jolla) for GIAPREZA(TM) (angiotensin II) and XERAVA(TM) (eravacycline). The agreement 
grants PAION an exclusive license for the commercialization of these two approved products in the European Economic 
Area, the United Kingdom and Switzerland (the Territories). 
GIAPREZA(TM) is approved by the European Commission as a vasoconstrictor indicated for the treatment of refractory 
hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume 
restitution and application of catecholamines and other available vasopressor therapies. XERAVA(TM) (eravacycline) is 
approved by the European Commission for the treatment of complicated intra-abdominal infections in adults. Both 
products are already launched in the U.S. and are showing strong revenue growth and potential. 
Under the terms of the license agreement, PAION has the exclusive right to commercialize GIAPREZA(TM) and XERAVA(TM) in 
the Territories, while bearing all future associated costs for the development, market authorization and distribution 
in the Territories. 
La Jolla will receive a USD 22.5 million upfront license fee payment. In addition, La Jolla is entitled to receive 
additional payments of up to USD 109.5 million contingent upon the achievement of certain commercial milestones, the 
majority of which are predicted upon reaching significant sales revenues. La Jolla is also entitled to royalties on 
PAION's own net sales in Europe in the amount of 15% for XERAVA(TM) and between 18% and 24% for GIAPREZA(TM) and a 
share of revenues from indirect sales. 
PAION will use current cash at hand of close to EUR 22 million (as of today) to settle the upfront payment and will 
draw the first two tranches of the loan facility from the European Investment Bank (EIB) in the amount of EUR 12.5 
million. The third tranche from the EIB loan in the amount of EUR 7.5 million is expected to be available shortly. 
With the addition of two more hospital products to its commercial portfolio, PAION has made the final decision to build 
out its own commercial structure in Europe to commercialize^GIAPREZA(TM) and XERAVA(TM) together with Byfavo^(R) after 
its potential market approval in Europe. 
A Market Approval Application (MAA) for Byfavo^(R) for procedural sedation is currently under review by the European 
Medicines Agency (EMA). PAION expects that the CHMP (Committee for Medicinal Products for Human Use) will publish its 
recommendation on the MAA by the end of January 2021. The European Commission will review the CHMP recommendation and a 
final decision is expected in the first half of 2021. PAION plans to have launched all three products by the end of 
2021. 
PAION will require additional funds to commercialize its product portfolio in selected European markets. The total 
funds required will depend on the structure of the commercial/distribution setup, as well as the magnitude and timing 
of incoming milestone and royalty payments from remimazolam licensees. These milestone and royalty payments could 
partially cover the funding requirements. Furthermore, PAION is looking into complementary financing measures to cover 
the funds required in the next years. 
End of inside information 
 
=---------------------------------------------------------------------------------------------------------------------- 
Information and Explanation of the Issuer to this News: 
PAION Contact 
Ralf Penner 
Director Investor Relations / Public Relations 
PAION AG 
Martinstrasse 10-12 
52062 Aachen - Germany 
Phone: +49 241 4453-152 
E-mail: r.penner@paion.com 
www.paion.com 
Disclaimer: 
This release contains certain forward-looking statements concerning the future business of PAION AG. These 
forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION 
AG's management as of the date of this release. They are subject to a number of assumptions and involve known and 
unknown risks, uncertainties and other factors. Should actual conditions differ from PAION AG's assumptions, actual 
results and actions may differ materially from any future results and developments expressed or implied by such 
forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely 
unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such 
forward-looking statements to reflect future events or developments. 
=---------------------------------------------------------------------------------------------------------------------- 
12-Jan-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and 
Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      PAION AG 
              Martinstr. 10-12 
              52062 Aachen 
              Germany 
Phone:        +49 (0)241-4453-0 
Fax:          +49 (0)241-4453-100 
E-mail:       info@paion.com 
Internet:     www.paion.com 
ISIN:         DE000A0B65S3 
WKN:          A0B65S 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1160053 
 
End of Announcement  DGAP News Service 
=------------

1160053 12-Jan-2021 CET/CEST

(END) Dow Jones Newswires

January 12, 2021 07:41 ET (12:41 GMT)